NCT06249191 - Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2027

Conditions

Diffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma

Interventions

PROCEDURE

Biopsy

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin

Given IV

PROCEDURE

Echocardiography

Undergo echocardiography

DRUG

Etoposide

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Mosunetuzumab

Given IV

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Positron Emission Tomography

Undergo PET scan

DRUG

Prednisone

Given PO

DRUG

Vincristine

Given IV

Trial Locations (1)

97239

RECRUITING

OHSU Knight Cancer Institute, Portland